IVERIC bio, Inc.
NASDAQ: ISEE0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Glenn P. Sblendorio
- Employees
- 163
- Headquarters
- Parsippany, United States
- IPO year
- 2013
- Market cap
- $5.5B
- Website
- https://ivericbio.com
Loading ISEE…
Loading profile data…Frequently asked questions about ISEE
What does IVERIC bio, Inc. (ISEE) do?
IVERIC bio, Inc. is a biopharmaceutical enterprise focused on identifying and advancing innovative therapeutic solutions for eye conditions, with a particular emphasis on age-related and rare inherited retinal diseases (IRDs). A cornerstone of its development pipeline is Zimura, an inhibitor targeting complement factor C5. This compound is curre...
Where does ISEE trade?
IVERIC bio, Inc. (ISEE) trades on the NASDAQ Global Select.
What sector is ISEE in?
IVERIC bio, Inc. (ISEE) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of IVERIC bio, Inc.?
Glenn P. Sblendorio is the chief executive officer of IVERIC bio, Inc. (ISEE).
Where is IVERIC bio, Inc. headquartered?
IVERIC bio, Inc. is headquartered in United States.
Does ISEE pay a dividend?
IVERIC bio, Inc. (ISEE) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ISEE go public?
IVERIC bio, Inc. (ISEE) completed its initial public offering in 2013.